Clinical trialEarly Phase 1Active not recruiting
Imaging Study of 18F-FAC PET Scans to Assess Standard Treatment in People With Pancreatic Cancer
18F-FAC PET Imaging to Quantify Gemcitabine Tumor Drug Uptake and Biodistribution in Pancreatic Cancer Patients
- Outcome
- Ongoing
- Phase
- Early Phase 1
- Status
- Active not recruiting
- Study type
- Interventional
- Start
- 18 November 2021
- Listed end
- 18 November 2026
- Enrollment
- 30 participants
- Sites
- 1
- Primary outcomes
- Tumor drug uptake within PDAC tumors prior at pre-treatment baseline
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 3 September 2026
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study is to find out whether a pre-treatment PET scan using the experimental imaging tracer 18F-FAC can show how much of the standard chemotherapy for PDAC may be taken up by the cancer.